With questions raised on prostate cancer benefit, Amgen's Xgeva may face tough ODAC
This article was originally published in Scrip
Executive Summary
The US FDA has only one question for its Oncologic Drugs Advisory Committee (ODAC) at its 8 February meeting: Has Amgen's RANK ligand inhibitor Xgeva (denosumab 120mg) demonstrated a favourable risk-benefit evaluation for the treatment of castrate resistant prostate cancer (CRPC) at high risk for metastasis?